retlirafusp,shr 2554
jiangsu hengrui pharmaceuticals
['shr-2554', 'lymphoma', 'shr-1701']
#hengrui's tgf- rii/ pd-l1, shr-1701 + ezh2i shr-2554 shows promising orr of 61.3% in ph1 study for sts, lymphoma; noteworthy orr of 100% was observed in r/r chl pts that warrants further evaluation - brings new hopes in the tgf- space
#asco23 #asco2023 #cancer 
Course5i prides itself in enabling #LifeSciences organizations with insights, #analytics and #AI to drive strategic decisions. Enabling better health outcomes.